The results of a multicenter clinical study validates the ability of its ImmunoXpert diagnostic blood test to assess whether a patient has an acute bacterial or viral infection.
In the PLOS One study, the ImmunoXpert immune signature was developed and independently validated on a cohort of 1002 patients with acute infections and yielded highly accurate results, with sensitivity and specificity greater than 90%.
The assay was validated in a diverse group of pediatric and adult patients at different time points after the onset of symptoms (from the first day up to 12 days) and across 56 different pathogen species. ImmunoXpert remained robust over all sub-groups studied. The predictive power of the assay’s immune signature outperformed routine biomarker and laboratory tests, as well as combinations of these tests.
The signature is amenable to rapid measurement using a blood test run on standard hospital and laboratory-deployed automated platforms, or using a point-of-care device now in development.
